Event at a glance
The World Congress brings the world’s most prominent regenerative medicine and longevity scientists together, presenting the new research, responsible drug development, novel therapies and commercialisation to target age-related diseases.
Tuesday 26 April
09:00 Welcome
Jade Osei-Tutu, Conference Director, LSX
09:05 Opening Remarks
Chairman:
Stephen Helliwell, VP discovery biology, Rejuveron,
09:10 Keynote Panel: Regenerative, Rejuvenate or Reprogram?
An in-depth discussion about the applying geroscience to regenerative and longevity research. Investigating how the deeper understanding of ageing biology can progress the next 10 years of stem cells and longevity therapeutics.
Speakers:
Thomas Rando, Co-Founder, Fountain Therapeutics
Georgina Ellison-Hughes, Professor of Regenerative Muscle Physiology, King's College London
Nir Barzilai, Director, Institute for Aging Research, Albert Einstein College of Medicine
Moderator:
James Peyer, CEO, Cambrian
09:55 Keynote Panel: The COVID-19 Impact
COVID-19, the disease caused by the coronavirus Sars-CoV-2, is most prevalent in older adults, causes more severe symptoms in this population and over 90% of deaths are in the over 65 year olds.
Gain insights into how COVID-19 has impacted on social issues and research data on ageing science, including describing how an aged immune system contributes to this increased morbidity and mortality in older adults and also discuss research into the long term consequences for immunity and overall health in COVID-19 survivors. Then discuss how any lesson learnt can be applied to improve healthspan going forward.
James Kirkland, Director of the Robert and Arlene Kogod Centre on Aging, Mayo Clinic
Janet Lord, Institute of Inflammation and Ageing, University of Birmingham
10:40 Morning Break
Longevity Therapeutics
Advancing mechanistic understanding
11:10 Presentation: Targeting Mechanisms Underlying the Biology of Aging to Treat and Reverse Disease
Exploring three platforms targeting key mechanisms underlying aging biology: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming. Therapies developed within each platform have the potential to prevent, treat, and/or reverse multiple aging-related diseases.
Jerry McLaughlin, CEO, Life Biosciences
11:35 Presentation: Harnessing endogenous immune biology to ablate pathogenic senescent cells and treat disease
12:00 Presentation: Data-informed drug discovery and clinical development for therapies that target aging
BioAge’s AI-based platform analyzes human aging to discover key longevity mechanisms, and then targets these pathways with drugs aimed at age-related conditions with clear regulatory strategies and well-defined patient populations. We will describe our human data–driven platform and the three mechanistically diverse clinical-stage programs it has inspired to date.
Kristen Fortney, Co-founder and Chief Executive Officer, BioAge Labs
Regenerative Medicine Track
Innovative technologies and mechanistic understanding
Chairwoman
Lynne Cox, PI Lab of Ageing and Cell Senescence, University of Oxford
11:10 Presentation: Understanding the role of cell senescence and homeostasis in targeting cardiac regeneration
Mammalian ageing is defined as a gradual loss of the capacity to maintain tissue homeostasis or to repair tissues after injury/stress. The adult heart is considered a post-mitotic organ, having a low cardiomyocyte turnover rate over the course of human lifespan, which decreases further with ageing.
Like other tissues and organs senescent cells accumulate in the heart with ageing and in chronic disease, contributing to pathophysiology and deterioration. Regulation of cell senescence will impact the efficacy of regenerative therapies, especially if the majority of patients in need of it are of advanced age as occurs with heart disease and failure.
Targeting cell senescence using senolytics can rejuvenate the aged hearts regenerative capacity.
Georgina Ellison-Hughes, Professor of Regenerative Muscle Physiology, King's College London
11:35 Presentation: Exploring the novel molecular mechanisms within the brain targeting Alzheimer’s disease that can be translated to the clinic
Examine how the relationship between cellular senescence and the chronic neurodegenerative diseases, including the mechanism around tau toxicities, impacts cellular senescence in the brain.
Miranda Orr, Assistant Professor, Gerontology and Geriatric Medicine, Wake Forest School of Medicine
12:00 Presentation: Reframing Health and Aging through the Lens of Reproductive Longevity
Ovarian aging is perhaps the most promising but overlooked area in aging science. Understanding why ovaries age prematurely may provide important clues about aging in the rest of the body; ovaries also represent an elusive human model to test longevity interventions on a relatively short timescale.
Reproductive aging is about far more than fertility or menopause and impacts a woman’s entire life experience: career, family, health and well-being – this is about equality. In this presentation we will discuss a global movement to advance scientific research focused on reproductive longevity to accelerate the pace of discovery toward useful therapies.
Jennifer Garrison, Co-Founder & Director, Global Consortium for Reproductive Longevity & Equality, and Assistant Professor, Buck Institute
12:25 Lunch
13:40 Panel: Target Ageing Beyond the Therapeutic
How is important is diet, sleep, stress, exercise, and genetics for ageing and treating chronic diseases approach? Is a low caloric diet essential? Explore recent findings around the data the impact stress and sleep have on the biological age.
Speakers:
Grace McNamara, Chief Executive Officer, EXi
Elena Gross, CEO/CSO and founder, KetoSwiss AG
Moderator:
Tina Woods, CEO, Collider Health
14:15 Presentation: Building and investing in longevity companies
Explore how company builder Maximon, identifies the most promising business opportunities in the field of longevity and builds companies from scratch. Learn about its proven structures, financing, and a unique and inspiring playground for entrepreneurs to build a longevity venture.
Tobias Reichmuth, Partner and Co-Founder, Maximon
14:25 Panel: De-risking ageing drug development
The right early-stage data is crucial to move beyond the concept stage and secure investment.
Review the tools that can accurately assess how well lead compounds slow down the process of ageing within early-stage research. Identify the key data for longevity drug discovery and address the hurdles to obtain the data.
Speakers:
David Weinkove, Co-Founder & CEO, Magnitude Biosciences
Tea Shavlakadze, Director of Aging/Age-Related disorders, Regeneron Pharmaceuticals
Joan Mannick,
Phil Newman,
15:05 Presentation: Longevity Ecosystem- Challenges and opportunities about building a full longevity indication
We, at the Longevity tech Fund are building a longevity ecosystem that addresses the needs of the longevity vertical as a whole rather than providing standalone solutions
Jyothi Devakumar, Chief Science Officer and Partner, Longevity Tech Fund
13:40 Presentation: Advancing aging frailty through the clinic with ageing clinical endpoints.
Hear the latest data in the advanced 150 patient enrolled trial targeting ageing frailty. Discover ageing biomarkers and clinical endpoints used for an aged, focused indication.
Explore whether the phase II trial with Lomecel-B is positive in reducing inflammation and improving physical function.
Joshua Hare, Co-Founder, Chief Science Officer and Chairman, Longeveron
14:05 Presentation: The role of Thermobalancing Therapy in extending healthspan in people with chronic diseases
Explore the essence of Thermobalancing Therapy and wearable Dr Allen's Devices as a novel and patented therapeutic treatment for different chronic health conditions, including kidney stone disease, benign prostate enlargement, chronic prostatitis, and back pain.
Discuss the impact of this safe non-invasive therapy on healthspan. Review data from 4 clinical trials and multiple patient case studies generated during 12-year long empirical observations.
Ariana Adjani, Co-founder, Fine Treatment
14.30 Presentation: A topical approach to reduce senescent cell accumulation in skin, our largest organ, to improve skin health markers and overall longevity
Cellular senescence is known to play a role in age-related skin function deterioration, justifying the need for the development of senotherapeutic approaches to extend skin health and prevent age-related skin disorders. OneSkin has developed a comprehensive platform to screen senotherapeutic peptides and validate its role in reducing skin biological aging and improve skin health markers in vitro and in clinical studies. The understanding of these and other events that influence skin aging and function are now paving the way for elucidating the impacts of age-related skin deterioration on overall organismal health.
Carolina Reis Oliveira, Founder and Chief Executive Officer, OneSkin
14:55 Genflow Biosciences: Could Gene Variant Found in Centenarians Boost Efforts to Develop Anti-aging Therapies?
Eric Leire, Co-founder & COO, BioAge
15:15 Afternoon Break
15:45 Panel: Translating and commercialising regenerative medicine and ageing science into therapeutics and consumer products
Assessing the route to market options by developing biologic or medical device designation. How do they differ in IP potential and market access parameters (pricing and reimbursement strategies)?
How important is buy in from big Pharma critical for commercialisation for regenerative products over companies establishing themselves as ‘big’ biopharma. Discussing how the advancements of regenerative medicine to translate real world interventions can be applied to longevity therapeutics and gain more interest from larger player and payers.
And assessing the market opportunities for rejuvenation applications that can be utilised direct-to-consumer such as wound management, skin care and dental care.
Ben Turner, Director - Venture Science, Eli Lilly and Company
Joshua Hare, Co-Founder, Chief Science Officer and Chairman, Longeveron
Saranya Wyles, Assistant Professor of regenerative medicine and dermatologist, Mayo Clinic School of Medicine
Moderator:
Nir Barzilai, Director, Institute for Aging Research, Albert Einstein College of Medicine
16:30 Roundtables
Siham Ceballos
17:45 Close of day 1 and Rejuvenate reception
09:00 Chair Opening Remarks
David Weinkove, Co-Founder & CEO, Magnitude Biosciences
09:05 Keynote Panel: Investment landscape within Regenerative medicine and Longevity Therapeutics
Removing the taboo of longevity and regenerative medicine within traditional biotech investment dynamics. Understand how the landscape is changing with new investment providers and deep dive into their due diligence process.
Alexandra Bause, Investor Director, Apollo Ventures
Ronjon Nag, Managing Director and Founder, R42 Group
Tobias Reichmuth, Co-Founder, Maximon
Petr Sramek, Managing Partner, Longevity Tech Fund
Moderator
Jennifer Garrison, Co-Founder & Director, Global Consortium for Reproductive Longevity & Equality, and Assistant Professor, Buck Institute
09:50 Fireside Chat: Rejuveron’s outlook on the next decade opportunity for aging science
A fireside chat with Rejuveron’s CEO, Matthias Steger who will share his thoughts on where he sees interesting approaches within longevity therapeutics and how Rejuveron are working with emerging biotechs to progress their science to clinical stages and commercial entities.
Matthias Steger, Chief Executive Officer, Rejuveron
Moderator:
Jerry McLaughlin, CEO, Life Biosciences
10:20 Panel: Commercialising skin with hard data
Sibylle Jager, Scientific Directorate Manager, L’Oréal
Stephanie Manson-Brown, Head of Clinical Development, VP Allergan Aesthetics R&D, AbbVie
Cristiana Banila, Chief Scientific Officer, MITRA BIO
Moderator:
Carolina Reis Oliveira, Founder and Chief Executive Officer, OneSkin
11:00 Morning Break
Ageing science: moving to the clinic
11:30 Panel: Challenges in clinical trials for longevity therapeutics
What are some common obstacles to clinical trials of longevity-based therapeutics — and what are the strategies that might be used to successfully overcome them? The panelists will discuss the challenge of indication selection, including an assessment of the decision process in previous p53 and mTOR longevity trials; the development of clinical tools for aging, including biomarkers and endpoints; navigating existing regulatory frameworks; and the impact (and value) of clinical trial “failures” as the field moves forward.
Joan Mannick, Co-Founder and CEO, Tornado Therapeutics
Jimmy El Hokayem, Programme Director, BioRasi
Jamie Dananberg, Chief Medical Officer, UNITY Biotechnology
Moderator:
Eric Morgen, CMO & COO, BioAge
12:10 Presentation: Targeting Aging with Metformin (TAME): A Concrete Plan to Pave the Way for Targeting Aging
12:35 Presentation: Macular degeneration clinical development via targeting BCL pathways
Explore ocular biology around the senescent triggers of disease and targeting the BCL-xL pathway as a senolytic mechanism. Discuss the lead compound through the clinic including early phase results.
Jamie Dananberg, Chief Medical Officer, UNITY Biotechnology
13:00 Lunch
14:15 Fireside Chat: Tackling Immunogenicity in gene therapy, cell therapy and organ transplantation
Discussing the triggers of allogenic graft rejection, the mechanistic understanding of immunogenicity and importance when developing cell and gene therapy.
Stefan Tullius, Professor of Surgery, Transplant Surgery, Harvard Medical School
Moderator:
Michael Hufford, Co-Founder and CEO, Lygenesis
14:40 Pre-clinical development of new senotherapeutics via modulation of RNA splicing
Lorna Harries, Chief Scientific Officer, Senisca
15:05 Presentation: Targeting age-related pathways to treat aging disorders
Tea Shavlakadze, Director of Aging/Age-Related disorders, Regeneron Pharmaceuticals
15:30 Presentation: Lymphatic Bioreactors, Ectopic Organs, and the Commercialization of Regenerative Medicine
15:55 Closing Remarks
16:00 Congress Closes
LSX is the Life Science eXecutive partnering community.
We connect biotech, medtech & healthtech executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses.
For updates follow us:
© 2020 All Rights Reserved By LSX Ltd | Privacy Policy